Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenkirchner

Showing results (21-30 of 125) with videos related to

Pageof 13
Sort By:
Zeitschrift Fur Rheumatologie|February 6, 2002
[IV: Small group workshop for developing future measures and projects. Evidence-based therapy in rheumatology with special reference to applications of new drugs--formulation of possible goals and possibilities for meeting them. Rheumatoid arthritis ]M Schattenkirchner
European Journal of Rheumatology and Inflammation|January 1, 1990
An updated safety profile of etodolac in several thousand patientsM Schattenkirchner
Wiener Klinische Wochenschrift. Supplementum|January 1, 1984
[Indications and contraindications for systemic gold therapy]M Schattenkirchner
MMW, Munchener Medizinische Wochenschrift|July 17, 1981
[Rheumatology forum. Part 2. Early diagnosis of chronic polyarthritis mostly by exclusion]M Schattenkirchner
Zeitschrift Fur Rheumatologie|September 1, 1996
[The time for gold therapy has not yet expired]M Schattenkirchner
Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin|January 1, 1986
[Clinical picture and diagnosis of gout]M Schattenkirchner
Zeitschrift Fur Rheumatologie|February 6, 2002
[New basic therapeutic drugs from the viewpoint of evidence-based therapy]M Schattenkirchner
Immunopharmacology|July 6, 2000
The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical reviewM Schattenkirchner
MMW, Munchener Medizinische Wochenschrift|July 1, 1983
[Rheumatology]M Schattenkirchner
Rheumatology International|January 1, 1993
The safety profile of sustained-release etodolacM Schattenkirchner
Pageof 13

Showing results (21-30 of 125) with videos related to

Sort By:
Pageof 13
Zeitschrift Fur Rheumatologie|February 6, 2002
[IV: Small group workshop for developing future measures and projects. Evidence-based therapy in rheumatology with special reference to applications of new drugs--formulation of possible goals and possibilities for meeting them. Rheumatoid arthritis ]M Schattenkirchner
European Journal of Rheumatology and Inflammation|January 1, 1990
An updated safety profile of etodolac in several thousand patientsM Schattenkirchner
Wiener Klinische Wochenschrift. Supplementum|January 1, 1984
[Indications and contraindications for systemic gold therapy]M Schattenkirchner
MMW, Munchener Medizinische Wochenschrift|July 17, 1981
[Rheumatology forum. Part 2. Early diagnosis of chronic polyarthritis mostly by exclusion]M Schattenkirchner
Zeitschrift Fur Rheumatologie|September 1, 1996
[The time for gold therapy has not yet expired]M Schattenkirchner
Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin|January 1, 1986
[Clinical picture and diagnosis of gout]M Schattenkirchner
Zeitschrift Fur Rheumatologie|February 6, 2002
[New basic therapeutic drugs from the viewpoint of evidence-based therapy]M Schattenkirchner
Immunopharmacology|July 6, 2000
The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical reviewM Schattenkirchner
MMW, Munchener Medizinische Wochenschrift|July 1, 1983
[Rheumatology]M Schattenkirchner
Rheumatology International|January 1, 1993
The safety profile of sustained-release etodolacM Schattenkirchner
Pageof 13